Premium
Chemotherapy and interferon‐α treatment of Erdheim–chester disease
Author(s) -
Jeon Insang,
Lee Sang Seon,
Lee Min Kyung
Publication year - 2010
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.22636
Subject(s) - medicine , erdheim–chester disease , histiocytosis , blood cancer , chemotherapy , langerhans cell histiocytosis , disease , alpha interferon , interferon , interferon α , pathology , dermatology , oncology , cancer , immunology
Erdheim–Chester disease (ECD) is a rare non‐Langerhans cell histiocytosis of an unknown origin. The prognosis of ECD is variable, and it mainly depends on the involved anatomic sites. The treatment modalities have not been standardized. Interferon‐α (IFN) has been reported to be effective in the management of ECD. We report here on an uncommon case with ECD in a 17‐year‐old female who had multiple lesions in the whole body and she was treated with chemotherapy and IFN. She has remained disease‐free for 2 years after the completion of treatment. Pediatr Blood Cancer. 2010;55:745–747. © 2010 Wiley‐Liss, Inc.